In a series of recent executive actions, Trump has signed multiple orders aimed at reducing prescription drug prices for Americans. These actions include significant steps to improve Medicare drug price negotiations and address soaring Medicare prescription drug costs. Trump has also expressed his support for changes to the Inflation Reduction Act, which have been sought by the pharmaceutical industry. Critics and supporters alike are closely monitoring how these measures will impact healthcare costs and pharmaceutical companies moving forward.